Healthcare Payers / Providers


May 13, 2026

Hospice / Home Health Moratorium Headwind & Advantages for Established Operators [CHE, PNTG, EHAB, BTSG]

By Beth Steindecker

CMS’s announcement of a six-month moratorium on new hospice and home health agency enrollment in Medicare is the latest escalation in the administration’s broader crackdown on alleged waste fraud, and abuse, reinforcing its ongoing targeting…

Read More >>

May 12, 2026

UNH’s Flat-Fee PBM Model Seems in Response to Rivals and Regulators [UNH, CI, CVS]

By Beth Steindecker

UNH’s new Optum Rx model, which shifts PBM and group purchasing organization compensation in its commercial business toward transparent flat fees, appears designed to modestly outpace similar transparency initiatives from CI and CVS while aligning…

Read More >>

May 7, 2026

Medicare Advantage: Policy Risk Panoply

By Beth Steindecker

With 1Q26 earnings now largely complete for the major Medicare Advantage (MA) insurers [UNH, HUM, ALHC, CVS, ELV, CNC, MOH], near-term MA policy risks remain less acute, though far from extinguished. Congressional cuts remain unlikely…

Read More >>

May 1, 2026

Medicaid Work Requirements: Despite Certain Restrictive Actions, Overall State Flexibility Likely Limits Risk [CNC, MOH, HCA, THC, UHS]

By Beth Steindecker

A wave of state actions (AR, IA, ID, IN, MO, MT, NC, NE, NH) on Medicaid community engagement requirements (aka work requirements), spanning both accelerated implementation like today’s launch in NE and in some cases,…

Read More >>

April 27, 2026

Dialysis – CY27 Medicare Bundle: Phosphate Binders and Monthly Add-on Remain Swing Factors [DVA, FRE.DE, Innovative Renal]

By Beth Steindecker

With the CY27 Medicare end-stage renal disease (ESRD) payment proposal now under OMB review, uncertainty surrounding the extra payments for oral phosphate binders to dialysis centers [DVA, FRE.DE, private Innovative Renal] may emerge as an…

Read More >>

April 24, 2026

Hospice: Program Integrity Still Overhang, but Large Agencies Insulated; How SSVI May Be Tweaked [CHE, PNTG, BTSG, ADUS, AVAH]

By Beth Steindecker

CHE’s comments on its 1Q26 earnings call this morning regarding the government’s efforts to rein in Medicare waste, fraud and abuse in hospice reinforce our prior views that program integrity, instead of the sufficiency of…

Read More >>

April 21, 2026

Another State PBM Ban on Pharmacies Invites Headline Noise – and Ultimately Legal Challenges [CVS, CI, UNH]

By Beth Steindecker

While the passage of another ban on PBM ownership of pharmacies – this time in Tennessee – could reignite some headline risk for CVS, CI, and UNH, we think the actual risk of it going…

Read More >>

April 21, 2026

Being Coy on BALANCE – How Could CMS and Insurers Get to Yes [UNH, ELV, HUM, CVS, CNC, CI, MOH]

By Beth Steindecker

UnitedHealth’s (UNH) comments on its earnings call this morning, responding to a question about potential participation in CMS’s BALANCE obesity drug model, suggest that further design changes will be required for it – and likely…

Read More >>

April 12, 2026

Inpatient Hospitals: Slight Medicare Growth for FY27, But Future Holds Mandatory Bundles and Less Automatic Bonuses for New Tech [HCA, THC, CYH, ENSG, PACS, PNTG]

By Beth Steindecker

FY27 Medicare reimbursement proposals for inpatient hospitals [HCA, THC, CYH, ARDT, UHS, MPT, muni-backed systems] largely met expectations for a smaller increase, versus FY26, with most changes appearing formulaic and math-based rather than policy-led. Despite…

Read More >>

April 8, 2026

Quarterly Policy Catalysts 2Q26: Health Insurers & Providers

By Beth Steindecker

With government policy in flux and CY/FY27 payment updates coming into focus, we outline key 2Q potential policy catalysts and debates for health insurers and providers. While CMS’s improved CY27 Medicare Advantage rates offer a…

Read More >>